We have had some discussions in the past about how Apabetalone may have some relevance for NASH.  There is an article on this liver disease in this weekend's Investor's Business Weekly.  It is more about the companies researching this disease, than about the science.

https://www.investors.com/news/technology/nash-liver-disease-treatment-biotech-companies-billions-sales/